{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:32:31Z","timestamp":1791016351801,"version":"4.1.0"},"reference-count":45,"publisher":"Japanese Pharmacological Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1254\/jphs.10r26fm","type":"journal-article","created":{"date-parts":[[2011,4,18]],"date-time":"2011-04-18T05:20:31Z","timestamp":1303104031000},"page":"30-35","source":"Crossref","is-referenced-by-count":12,"title":["Novel Situations of Endothelial Injury in Stroke \u2014 Mechanisms of Stroke and Strategy of Drug Development: Protective Effects of Antiplatelet Agents Against Stroke"],"prefix":"10.1254","volume":"116","author":[{"given":"Masamitsu","family":"Shimazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07493-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587.","DOI":"10.1056\/NEJM199512143332401"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000016405.06729.83"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Feng W, Hendry RM, Adams RJ. Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology. 2010;74:588–593.","DOI":"10.1212\/WNL.0b013e3181cff776"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry. 1996;60:197–199.","DOI":"10.1136\/jnnp.60.2.197"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25:2331–2336.","DOI":"10.1161\/01.STR.25.12.2331"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)00498-5"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.24.11693"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood. 1994;83:885–898.","DOI":"10.1182\/blood.V83.4.885.bloodjournal834885"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Graham DY. The relationship between nonsteroidal anti-inflammatory drug use and peptic ulcer disease. Gastroenterol Clin North Am. 1990;19:171–182.","DOI":"10.1016\/S0889-8553(21)00463-5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787–796.","DOI":"10.7326\/0003-4819-115-10-787"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Micieli G, Cavallini A. New therapeutic strategies with antiplatelet agents. Neurol Sci. 2001;25 Suppl 1:S13–S15.","DOI":"10.1007\/s10072-004-0209-4"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92327-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989;321:501–507.","DOI":"10.1056\/NEJM198908243210804"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)00308-5"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00346-9"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(98)00189-3"},{"issue":"7a","key":"19","first-page":"1144","volume":"35","author":"Kimura Y., Tani T., Kanbe T., Watan","year":"1985","ISSN":"https:\/\/id.crossref.org\/issn\/0004-4172","issn-type":"print"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1053\/jscd.2000.7216"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70198-8"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68734-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9:489–497.","DOI":"10.1016\/S1474-4422(10)70060-0"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.08077SC"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000170642.39876.f2"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.22.1930"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16721-4"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060989"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00395-0"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(99)00109-7"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, et al. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke. 1989;20:668–673.","DOI":"10.1161\/01.STR.20.5.668"},{"issue":"7a","key":"32","first-page":"1149","volume":"35","author":"Kawamura K, Watanabe K, Kimura Y","year":"1985","ISSN":"https:\/\/id.crossref.org\/issn\/0004-4172","issn-type":"print"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1179\/016164105X17134"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.3.787"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Lee JH, Lee YK, Ishikawa M, Koga K, Fukunaga M, Miyakoda G, et al. Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats – an MRI study. Brain Res. 2003;994:91–98.","DOI":"10.1016\/j.brainres.2003.09.021"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Lee JH, Kim KY, Lee YK, Park SY, Kim CD, Lee WS, et al. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J Pharmacol Exp Ther. 2004;308:896–903.","DOI":"10.1124\/jpet.103.061853"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat. Brain Res. 2007;1152:182–190.","DOI":"10.1016\/j.brainres.2007.03.035"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury. CNS Neurosci Ther. 2008;14:143–152.","DOI":"10.1111\/j.1527-3458.2008.00042.x"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2006.07.125"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(03)01029-2"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2009.01.039"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.2.709"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2004.05.002"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Park SY, Lee JH, Kim CD, Lee WS, Park WS, Han J, et al. Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation. J Pharmacol Exp Ther. 2006;317:1238–1245.","DOI":"10.1124\/jpet.105.098509"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.077826"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T20:30:24Z","timestamp":1637526624000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/116\/1\/116_10R26FM\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.10r26fm","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}